CGP 19984

01/01/1989 - "At concentrations ranging between 1 and 25 micrograms/ml, CGP 19984 inhibited growth of the prostate tumor epithelial cells in a dose-dependent manner. "
08/15/1988 - "Intact tumor-bearing Wistar/Furth female rats were administered vehicle or 25, 100, or 250 mg/kg CGP 19984 p.o., 5 x week for 4 weeks. "
08/15/1988 - "In a third study, bromocryptine (CB-154; 5 mg/kg) and CGP 19984 (50 mg/kg) were both found to be effective in suppressing growth of the MtT-W10 tumor in intact female rats. "
04/01/1986 - "However, the inhibitory effect of CGP 19984 on the growth of the MTW-9B tumor does not appear to be mediated by the action of the drug to lower estrogen levels, since this tumor is not dependent on estrogen for growth, and lower doses of CGP 19984 were found to be equally effective in reducing uterine weight, but had no antitumor activity. "
04/01/1986 - "The ability of CGP 19984 to suppress gonadal function and to inhibit tumor growth suggests that this drug may have potential clinical application in the treatment of both hormone-dependent and -independent prostate and breast cancers."

01/01/1989 - "The results thus demonstrate a direct effect of CGP 19984, which complements its indirect antitumor action in vivo, and suggest that this drug might be an effective agent for treatment of prostatic cancer. "
01/01/1989 - "Short-term primary culture of rat prostate tumor epithelial cells on reconstituted basement membrane as a useful in vitro model to assess drug action on prostatic cancer: efficacy of the thiazolidinedione derivative CGP 19984."

08/15/1988 - "Effects of the thiazolidinedione derivative CGP 19984 on growth and endocrine function of the MtT-W10 transplantable mammosomatotropic pituitary tumor in female rats."
08/15/1988 - "A similar study in ovariectomized rats also showed that CGP 19984 treatment suppressed MtT-W10 pituitary tumor growth, weight and hormone secretion in a dose-responsive manner, suggesting a direct inhibitory action of this drug on the tumor. "
08/15/1988 - "These results suggest that CGP 19984 effectively inhibits growth and hormone secretion of the autonomous MtT-W10 pituitary tumor by apparently suppressing both somatotropic and lactotropic cell populations within the tumor. "
08/15/1988 - "The present study examines the effects of CGP 19984 on the growth and hormone secretion of the autonomous, but estrogen-responsive, MtT-W10 mammosomatotropic transplantable rat pituitary tumor. "
08/15/1988 - "Furthermore, these findings indicate that CGP 19984 may be an effective alternative to CB-154 in the clinical treatment of prolactin-producing adenomas, as well as other types of pituitary adenomas."

04/01/1986 - "The antitumor efficacy and the hormonal effects of the thiazolidine-dione derivative (sodium methyl((-3-methyl-2- ([5-methyl-3-(2-methylallyl)-4-oxo-2 thiazolidinyliden]hydrazono)-4-oxo-5-thiazolidinyl)) phosphate, CGP 19984, have been studied in in vivo rat prostatic and mammary cancer models. "

04/01/1986 - "Animals showed no adverse effects from CGP 19984 except for a modest loss of body weight. "